The UK and US have secured a key trade agreement that will maintain no levies on British drug products going into the US market.
Agreement Details of the Accord
In exchange for the tariff guarantee, the UK has committed to raise expenditure on medicines through the National Health Service (NHS). This pledge guarantees that tariffs on these vital goods will remain at zero for a timeframe of three years.
This deal follows earlier statements to dramatically increase import taxes on branded pharmaceutical imports, with figures mentioned up to 100%.
"This deal with the United Kingdom bolsters the international landscape for cutting-edge drugs and introduces much-needed equity to transatlantic pharmaceutical trade," a release declared.
Trade Impact
Drugs are one of the UK's largest goods shipped to the America, which is by far the biggest buyer for major British pharmaceutical firms.
Export figures indicate that in the one-year period leading up to last September, the UK sold drugs worth over eleven billion pounds to the US. This value made up 17.4% of total UK exports in that span.
"This deal protects work, stimulates investment and paves the way for the UK to emerge as a worldwide center for life sciences," the Business and Trade Secretary stated.
Key British Pledges
The deal involves several specific pledges from the United Kingdom:
- Higher Cost Ceiling: The UK will raise the cost ceiling at which it considers new medicines to be unaffordable by 25%.
- Increased NHS Spending: There is a target to increase overall NHS spending on medicines from 0.3% of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Payback Limit: The amount drug companies must return to the NHS to control costs will be limited at fifteen percent. Previously, refunds topped twenty percent.
Recent Tensions
The deal takes place against a long-running row between the sector and the British authorities over medicine costs and approval rates.
These tensions were intensified by arguments that US consumers were paying several times more for the equivalent treatments than people in the Britain and the EU.
In recent months, several significant drug company projects in the UK have been halted or cancelled, while substantial expansions have been announced toward US facilities.
A senior figure acknowledged that the NHS needed to spend more on drugs, noting that its expenditure on drugs had decreased as a percentage of its total funding over the previous ten-year period.
